Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,485 | 278 | 1,166 |
| Samples | 681 | 189 | 480 |
| Peptides | 656 | 188 | 470 |
Function
APC2 · APC regulator of Wnt signaling pathway 2
This gene encodes a strongly conserved protein that has an N-terminal coiled-coil domain followed by an armadillo domain, five 20-amino acid repeats, and two SAMP domains. This protein promotes the assembly of a multiprotein complex that recruits and phosphorylates the Wnt effector beta-catenin and targets beta-catenin for ubiquitylation and proteasomal degradation. This protein therefore plays a role in the reduction of cytoplasmic levels of beta-catenin which in turn reduces activation of Wnt target genes that play a pivotal role in the pathogenesis of various human cancers. The protein encoded by this gene is closely related to the adenomatous polyposis coli (APC) tumor-suppressor protein and has similar tumor-suppressor effects. This gene also plays a role in actin assembly, cell-cell adhesion, and microtubule network formation through its interaction with cytoskeletal proteins. This gene has its highest expression in the central nervous system and is involved in brain development through cytoskeletal regulation in neurons. Alternative splicing produces multiple transcript variants encoding distinct isoforms. [provided by RefSeq, May 2017].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 514 amino-acid changes on canonical ENST00000233607 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in APC2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in APC2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Burkitts Lymphoma | 8/32 25% | 0/196 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 53/1592 3% |
| Endometrial Carcinoma | 13/42 31% | 8/612 1% |
| Melanoma | 11/210 5% | 54/1899 3% |
| Colorectal Carcinoma | 25/143 17% | 79/3239 2% |
| Gastric Carcinoma | 6/74 8% | 50/1809 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Neuroendocrine Tumour | 12/154 8% | 3/577 1% |
| Bladder Carcinoma | 4/58 7% | 15/956 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 19/1390 1% |
| Other Sarcomas | 4/69 6% | 9/699 1% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Cervical Carcinoma | 1/35 3% | 6/422 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Biliary Tract Carcinoma | 4/54 7% | 11/950 1% |
| Other Solid Cancers | 1/94 1% | 22/1515 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 9/810 1% |
| Mesothelioma | 2/62 3% | 1/165 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 26/2550 1% |
| Ovarian Carcinoma | 8/109 7% | 4/998 0% |
| Head and Neck Carcinoma | 5/85 6% | 12/1574 1% |
| Hepatocellular Carcinoma | 4/46 9% | 18/2210 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Kidney Carcinoma | 3/85 4% | 13/1862 1% |
Mutation Distribution
Where APC2 is mutated · all tissues, split by cell line vs tissue
How many mutations in APC2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,485 mutations in APC2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|